文献速递脑血管病认知障碍与痴呆

MarkVCID2联盟:脑小血管病生物标志物临床验证框架与基线特征

MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and Baseline Characteristics.
PubMed 文献 · Ann Neurol · 2025-09-22

MarkVCID2联盟在17个中心纳入1883名60-90岁参与者,旨在建立脑小血管病(SVD)候选生物标志物的验证框架。基线评估显示44.8%为临时高风险,经MRI裁定后48.5%为裁定高风险,存在显著风险重分类。该队列将进行3年纵向随访以验证生物标志物用于受试者选择和结局测量。

要点

  • MarkVCID2纳入1883名多族裔参与者,富集认知症状和SVD危险因素。
  • 基线临时高风险44.8%,MRI裁定后高风险48.5%,风险分类变动显著。
  • 3年随访将验证生物标志物用于SVD进展预测和结局评估。

核心结论

  • MarkVCID2基线数据表明成功纳入了富集SVD相关认知下降因素的多样化个体。
  • 将在3年纵向随访中验证候选生物标志物用于受试者选择和结局测量两个预期用途。

研究设计与样本

  • 多中心联盟研究,纳入60-90岁参与者,覆盖17个MarkVCID2站点。
  • 招募针对认知症状、 defined危险因素及Black/African American、White和Hispanic/Latino亚组进行富集。
  • 基线访视包括认知测试、多模态MRI和生物流体采集。

主要发现

  • 共纳入1883人,年龄73.4 ± 7.5岁,65.0%女性,24.2% Hispanic,27.1%非Hispanic Black。
  • 44.8%被临时指定为高风险。
  • 基线MRI后48.5%被归类为裁定高风险状态,存在从低到高(主要因无SVD危险因素的MRI病灶)和高到低(主要因基线测试未确认筛查时的疑似认知障碍)的显著重分类。

关键数值与推荐

  • 临时SVD相关认知下降风险主要基于基线认知症状加SVD危险因素估计。
  • 裁定风险状态基于认知症状加基线MRI上中重度白质高信号、微出血或腔隙灶的存在。

临床怎么用

  • 该框架可用于SVD相关认知下降的风险分层,结合认知症状、危险因素和MRI病灶进行综合评估。
  • 生物标志物验证后将有助于选择可能从干预中获益的受试者和高效测量SVD进展。

局限性

  • 原文未报告生物标志物验证结果,需等待3年纵向随访分析。
  • 风险重分类可能受筛查时疑似认知障碍未确认等因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To establish a framework for validating candidate biomarkers of cerebral small vessel diseases (SVD) associated with cognitive impairment and characterize individuals enrolled by the MarkVCID2 consortium under this framework. METHODS: Participants age 60 to 90 years were enrolled across 17 MarkVCID2 sites. Recruitment was targeted to enrich in cognitive symptoms (mild dementia, mild cognitive impairment, subjective cognitive decline), defined risk factors (diabetes mellitus, advanced hypertension), and Black/African American, White, and Hispanic/Latino subgroups. Enrolled participants underwent baseline visits that included cognitive testing, multimodal magnetic resonance imaging (MRI), and biofluid collection. Provisional risk for SVD-related cognitive decline was estimated primarily by baseline cognitive symptoms plus SVD risk factors. Adjudicated risk status was estimated by cognitive symptoms plus presence of moderate-to-severe white matter hyperintensities, microbleeds, or lacunes on baseline MRI. RESULTS: MarkVCID2 enrolled 1883 individuals age 73.4 ± 7.5 years, 65.0% female, 24.2% Hispanic, and 27.1% non-Hispanic Black. Among enrollees, 44.8% were provisionally designated high-risk. After baseline MRI, 48.5% were categorized as adjudicated high-risk status, with substantial recategorization both from low- to high-risk (primarily because of MRI lesions without SVD risk factors) and high- to low-risk (primarily suspected cognitive impairment at screening not confirmed by baseline testing). INTERPRETATION: MarkVCID2 baseline data indicate successful enrollment of diverse individuals enriched in factors associated with SVD-related cognitive decline. Changes over 3 years of longitudinal follow-up will be analyzed to validate the candidate biomarkers for 2 projected contexts of use: subject selection (identifying likelihood of future SVD progression) and study outcome (efficiently measuring SVD progression). ANN NEUROL 2026;99:449-458.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Greenberg SM, Albert MS, An H, et al. MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and Baseline Characteristics. Ann Neurol. 2025. PMID: 40977537. doi:10.1002/ana.78040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。